EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC 4.0

The effect of low-dose aspirin on reversing frailty status in older prefrail and frail adults: a secondary analysis of the ASPREE randomised clinical trial

Ananta P Handono, Joanne Ryan iD, Fajar Setiawan iD, Sara E Espinoza, Aung Zaw Zaw Phyo iD, Chao Zhu iD, Mark R Nelson, Michael E Ernst iD, Suzanne G Orchard, Rory Wolfe iD, Robyn Woods iD, Peng Qiu and 1 more

Age and Ageing · 2025

DOI: 10.1093/ageing/afaf271 ↗

At a glance

Randomisierte kontrollierte Studie in Age and Ageing, 2025. Written by Ananta P Handono and 12 co-authors. Institution: School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. Major MEDLINE topics: Aspirin, Frailty, Frail Elderly, Anti-Inflammatory Agents, Non-Steroidal. Cited 3 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Chronic low-grade inflammation is hypothesised as a central driver of frailty. This study aims to evaluate whether low-dose aspirin can reverse frailty status among initially prefrail/frail older adults.

Methods

This was a post hoc subgroup analysis of the Aspirin in Reducing Events in the Elderly (ASPREE), a randomised, placebo-controlled trial, involving community-dwelling adults aged ≥65 years. The median (Interquartile range) follow-up was 4.7 (3.6–5.7) years. We included participants who were prefrail or frail at baseline, with frailty assessed using two validated measures: the Fried Frailty Phenotype (FFP) and the Deficit-Accumulation Frailty Index (FI). Frailty reversal was defined as a transition to a less severe state (from frail to prefrail/nonfrail, prefrail to nonfrail). The discrete-time survival model was used for outcome analysis; linear mixed-effects models compared longitudinal frailty trajectories between the treatment arms.

Results

Among 6595 and 8766 participants included in the FFP and FI analyses, respectively, there was no significant difference in frailty status reversal between aspirin and placebo groups (FFP-HR: 1.00, 95% CI: 0.92–1.07; FI-HR: 1.00, 95% CI: 0.94–1.07). No significant difference was found in the change of FFP counts (β = 0.014, SE = 0.007, P = .06) and FI score (β = 0.0004, SE = 0.004, P = .37) between the aspirin and placebo groups over time, suggesting that aspirin neither reversed nor worsened frailty severity. Subgroup analyses revealed no effect modification by frailty risk factors such as age, sex, race and medical history.

Conclusion

Low-dose aspirin has no effect in reversing frailty among prefrail and frail individuals. The findings highlight the need to explore alternative anti-inflammatory medications for frailty management.

Subjects

MeSH terms (MEDLINE)

AspirinFrailtyFrail ElderlyAnti-Inflammatory Agents, Non-SteroidalHumansAgedMaleFemaleAged, 80 and overGeriatric AssessmentTreatment OutcomeAge FactorsTime Factors

Author keywords

agedaspirinfrailtyolder peoplerandomised trial

Substances

AspirinAnti-Inflammatory Agents, Non-Steroidal

Authors and institutions

  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
  • Faculty of Medicine, Universitas Indonesia, Depok, Indonesia.
  • Sam and Ann Barshop Institute for Longevity and Aging Studies, UT Health San Antonio - Division of Geriatrics, Gerontology and Palliative Medicine, San Antonio, TX, USA.
  • Geriatrics Research, Education and Clinical Center, VA South Texas Veterans Health Care System, San Antonio, TX, USA.
  • School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
  • Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia.

ORCID profiles: Joanne Ryan, Fajar Setiawan, Aung Zaw Zaw Phyo, Chao Zhu, Michael E Ernst, Rory Wolfe, Robyn Woods, Zhen Zhou

Cite

APA

Handono, A. P., Ryan, J., Setiawan, F., Espinoza, S. E., Phyo, A. Z. Z., Zhu, C., Nelson, M. R., Ernst, M. E., Orchard, S. G., Wolfe, R., Woods, R., Qiu, P., & Zhou, Z. (2025). The effect of low-dose aspirin on reversing frailty status in older prefrail and frail adults: a secondary analysis of the ASPREE randomised clinical trial. Age and Ageing. https://doi.org/10.1093/ageing/afaf271

Vancouver

Handono AP, Ryan J, Setiawan F, Espinoza SE, Phyo AZZ, Zhu C, et al. The effect of low-dose aspirin on reversing frailty status in older prefrail and frail adults: a secondary analysis of the ASPREE randomised clinical trial. Age and Ageing. 2025. doi:10.1093/ageing/afaf271

BibTeX
@article{Handono2025,
  author = {Handono, Ananta P and Ryan, Joanne and Setiawan, Fajar and Espinoza, Sara E and Phyo, Aung Zaw Zaw and Zhu, Chao and Nelson, Mark R and Ernst, Michael E and Orchard, Suzanne G and Wolfe, Rory and Woods, Robyn and Qiu, Peng and Zhou, Zhen},
  title = {The effect of low-dose aspirin on reversing frailty status in older prefrail and frail adults: a secondary analysis of the ASPREE randomised clinical trial},
  journal = {Age and Ageing},
  year = {2025},
  doi = {10.1093/ageing/afaf271}
}
Start for free →